1. Generics Bulletin
  2. >>Products

‘What’s Really Important Is, What Are We Doing Next?’: Sandoz On Biosimilar Ambitions

Adalimumab, Denosumab, Natalizumab, And Aflibercept All Under Discussion

 
• By Dean Rudge

In the second part of Generics Bulletin’s exclusive interview with Sandoz’s global head for biosimilars, Peter Stenico, he discusses the company’s various near-term pipeline opportunities, as well as his expectations for LOE opportunities in the next decade.

Sandoz logo on building
• Source: Shutterstock

While it may have one of the broadest biosimilar pipelines in the industry, with 24 assets in various stages of development and regulatory filing, Sandoz will continue to focus on the quality of its future offerings, especially as new and uncharted opportunities arise at the beginning of the next decade.

“You need to be really thinking how do I select the assets? What needs to be in place from a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Cingulate Installs Interim Leadership After CEO Put On Administrative Leave

 
• By Dean Rudge

Shortly after filing its lead candidate for ADHD through the FDA’s 505(b)(2) hybrid new drug application pathway, Cingulate has appointed interim leadership after placing chairman and CEO Shane Schaffer on administrative leave over legal matters unrelated to the company.

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar

 
• By Dean Rudge

Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By Dave Wallace

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.